BioTuesdays

Tag - hepatitis B

Spring Bank heading into data-rich 2020

Spring Bank Pharmaceuticals (NASDAQ:SBPH) will be reporting clinical data readouts throughout 2020 as it advances a portfolio of three drug candidates for the treatment of chronic hepatitis B virus (HBV) as well as...

Arbutus taking multi-faceted approach to HBV

Arbutus Biopharma (NASDAQ:ABUS) is developing a portfolio of drug candidates, each with different mechanisms of action that it believes will result in a combination therapy to cure patients infected with hepatitis B...

William Blair analyst discusses Hep B space

As a partner and biotechnology analyst with William Blair & Co., Y. Katherine Xu was recognized in 2010 by the Financial Times/StarMine “World’s Top Analysts” listing, ranking No. 7 overall for stock-picking in the...

Subscribe

Sign up to our weekly BioTuesdays newsletter.